New hope for Hard-to-Treat myeloma? early trial tests Two-Drug attack

NCT ID NCT05139225

Completed Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This early-phase study tests a combination of two drugs—TTI-622 and daratumumab—in people whose multiple myeloma has returned or is not responding to treatment. The main goal is to find a safe dose of TTI-622 when given with daratumumab. Only 7 participants are enrolled, so the focus is on safety, not yet on how well the combo works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TTI-622 (a protein that blocks CD47) and daratumumab (a targeted antibody)
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for people with multiple myeloma that has returned or stopped responding to other therapies.
What could go wrong: This is a very early phase 1 trial with only 7 participants, so it is too small to prove effectiveness. The main goal is safety, and side effects or lack of benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.